By Rob Curran
Dyne Therapeutics received fast-track designation from the Food and Drug Administration for a treatment of myotonic dystrophy type 1, a neuromuscular disease.
The Waltham, Mass., developer of biotech treatments for muscle diseases said its DYNE-101 product candidate, which is currently being tested in an early-stage Phase 1/2 clinical trial, received the fast-track designation, which the agency uses to expedite development of drugs for unmet needs. Dyne noted the fast-track status will make its drug eligible for a rolling review, enabling it to submit sections of the Biologic License Application for review as they are ready, rather than the company needing to complete all development steps before receiving input from the FDA.
Dyne anticipates filing for accelerated approval of the treatment in the first half of 2026.
"[Myotonic dystrophy type 1] is a devastating disease with no approved therapies," said Doug Kerr, chief medical officer of Dyne, in a statement.
Myotonic dystrophy is a genetic condition that causes muscle wasting and other debilitating symptoms.
Shares of Dyne was up 6.2% premarket.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
January 21, 2025 08:05 ET (13:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。